AU2002319223A1 - Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein - Google Patents

Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein

Info

Publication number
AU2002319223A1
AU2002319223A1 AU2002319223A AU2002319223A AU2002319223A1 AU 2002319223 A1 AU2002319223 A1 AU 2002319223A1 AU 2002319223 A AU2002319223 A AU 2002319223A AU 2002319223 A AU2002319223 A AU 2002319223A AU 2002319223 A1 AU2002319223 A1 AU 2002319223A1
Authority
AU
Australia
Prior art keywords
metastases
binding molecule
sialoprotein
medicament
molecule against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002319223A
Other languages
English (en)
Inventor
Franz Paul Armbruster
Martin R. Berger
Ulf Jorg Forsmann
Markus Karmatschek
Werner Franz Nader
Mats Paulsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSTEOPEP-PHARMA GmbH
Original Assignee
OSTEOPEP PHARMA GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OSTEOPEP PHARMA GmbH filed Critical OSTEOPEP PHARMA GmbH
Publication of AU2002319223A1 publication Critical patent/AU2002319223A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002319223A 2001-06-13 2002-06-12 Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein Abandoned AU2002319223A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01114388.0 2001-06-13
EP01114388 2001-06-13
DE10128639 2001-06-15
DE10128639.2 2001-06-15
PCT/EP2002/006456 WO2002100899A2 (de) 2001-06-13 2002-06-12 Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein

Publications (1)

Publication Number Publication Date
AU2002319223A1 true AU2002319223A1 (en) 2002-12-23

Family

ID=26009516

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002319223A Abandoned AU2002319223A1 (en) 2001-06-13 2002-06-12 Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein

Country Status (10)

Country Link
US (2) US7825219B2 (cg-RX-API-DMAC7.html)
EP (1) EP1399186B1 (cg-RX-API-DMAC7.html)
JP (1) JP4570355B2 (cg-RX-API-DMAC7.html)
AT (1) ATE448796T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002319223A1 (cg-RX-API-DMAC7.html)
DE (1) DE50214008D1 (cg-RX-API-DMAC7.html)
DK (1) DK1399186T3 (cg-RX-API-DMAC7.html)
ES (1) ES2336770T3 (cg-RX-API-DMAC7.html)
PT (1) PT1399186E (cg-RX-API-DMAC7.html)
WO (1) WO2002100899A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1514929A1 (en) * 2003-09-12 2005-03-16 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Antisense oligonucleotides for prevention of metastasis formation of cancer cells
EP1888631B1 (de) 2005-05-31 2009-09-23 Ralf Jochem Therapeutsche zusammensetzung zur vorbeugung und bekämpfung von knochenmetastasen
WO2007038397A2 (en) * 2005-09-26 2007-04-05 Novartis Ag Molecular markers associated with bone metastasis
MX2011001930A (es) * 2008-08-29 2011-04-21 Symphogen As Metodo para clonar anticuerpos derivados de aves.
WO2016026917A2 (en) * 2014-08-19 2016-02-25 Immundiagnostik Ag Medicament and apparatus for treating chronic kidney disease
US20250084183A1 (en) * 2021-07-20 2025-03-13 William Marsh Rice University Engineered compositions for bone-targeted therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853219A (en) * 1987-08-06 1989-08-01 President And Fellows Of Harvard College Antibodies to angiogenin: immunotherapeutic agents
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5340934A (en) * 1989-11-03 1994-08-23 The United States Of Americas As Represented By The Secretary Of Health & Human Services CDNA sequences of human bone matrix proteins
DK0590058T3 (da) * 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
CA2370018A1 (en) * 1999-04-09 2000-10-19 Larry W. Fisher Complex formed by n-linked glycoproteins (siblings) and factor h

Also Published As

Publication number Publication date
PT1399186E (pt) 2010-02-23
WO2002100899A2 (de) 2002-12-19
JP4570355B2 (ja) 2010-10-27
DK1399186T3 (da) 2010-03-29
ATE448796T1 (de) 2009-12-15
US8808691B2 (en) 2014-08-19
WO2002100899A3 (de) 2003-12-18
JP2005506959A (ja) 2005-03-10
US20110091379A1 (en) 2011-04-21
ES2336770T3 (es) 2010-04-16
EP1399186A2 (de) 2004-03-24
DE50214008D1 (de) 2009-12-31
US7825219B2 (en) 2010-11-02
US20050069547A1 (en) 2005-03-31
EP1399186B1 (de) 2009-11-18

Similar Documents

Publication Publication Date Title
TR200102707T2 (tr) AĞrì hafifletme, kemik kanseri terapisi ve kemik yzeyinin saĞlìklì tutulmasì i‡in kire‡lenmiç hedef dokulara y”nelik radyum-223 hazìrlanmasì ve kullanìmì.
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
CY1109661T1 (el) 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης
DE60023476D1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
EP2301531A3 (en) Combinations and modes of administration of therapeutic agents and combination therapy
EP1558220A4 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
SG157951A1 (en) Cripto blocking antibodies and uses thereof
WO2002087555A3 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
WO2003030934A3 (en) Cpg formulations and related methods
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
WO2003090695A3 (en) TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
TW200612987A (en) Combination treatment for non-hematologic malignancies
WO2004043341A3 (en) Treatment for hemorrhagic shock
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
GB0020504D0 (en) Therapeutic method
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
AU2002319223A1 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
WO2000061141A3 (en) Methods and compositions for enhancing delivery of therapeutic agents to tissues
MXPA04001912A (es) Aminobenzofenonas novedosas.
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
SE9902597D0 (sv) New use
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase